123 related articles for article (PubMed ID: 1682379)
1. Specific pathogen-free BALB/cAn mice are refractory to plasmacytoma induction by pristane.
Byrd LG; McDonald AH; Gold LG; Potter M
J Immunol; 1991 Nov; 147(10):3632-7. PubMed ID: 1682379
[TBL] [Abstract][Full Text] [Related]
2. Pristane induces an indomethacin inhibitable inflammatory influx of CD4+ T cells and IFN-gamma production in plasmacytoma-susceptible BALB/cAnPt mice.
McDonald AH; Degrassi A
Cell Immunol; 1993 Jan; 146(1):157-70. PubMed ID: 8425224
[TBL] [Abstract][Full Text] [Related]
3. Plasmacytoma-refractory BALB/cAnPt mice have naive T cell and highly specific B cell responses to antigen.
McDonald AH; Byrd LG; Mainhart CR; Sopher J; Smith-Gill SJ
Mol Immunol; 1996 Oct; 33(15):1183-96. PubMed ID: 9070667
[TBL] [Abstract][Full Text] [Related]
4. BCL2 accelerates inflammation-induced BALB/c plasmacytomas and promotes novel tumors with coexisting T(12;15) and T(6;15) translocations.
Silva S; Kovalchuk AL; Kim JS; Klein G; Janz S
Cancer Res; 2003 Dec; 63(24):8656-63. PubMed ID: 14695177
[TBL] [Abstract][Full Text] [Related]
5. Induction of plasma cell tumours with 2,6,10,14-tetramethylpentadecane (pristane) and paraffin oil (paraffinum perliquidum) in BALB/c mice simultaneously exposed to sustained antigenic stimulation with bovine serum albumin (BSA).
Janz S; Püschel W; Raabe F; Storch H
Arch Geschwulstforsch; 1987; 57(1):25-30. PubMed ID: 3566462
[TBL] [Abstract][Full Text] [Related]
6. The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB/c mice by intraperitoneal injection of pristane.
Avcu F; Ural AU; Yilmaz MI; Ozcan A; Ide T; Kurt B; Yalcin A
Eur J Haematol; 2005 Jun; 74(6):496-500. PubMed ID: 15876253
[TBL] [Abstract][Full Text] [Related]
7. Genetics of susceptibility to pristane-induced plasmacytomas in BALB/cAn: reduced susceptibility in BALB/cJ with a brief description of pristane-induced arthritis.
Potter M; Wax JS
J Immunol; 1981 Oct; 127(4):1591-5. PubMed ID: 7276572
[TBL] [Abstract][Full Text] [Related]
8. Disposition of the plasmacytomagenic alkane pristane (2,6,10,14-tetramethylpentadecane) in mice.
Janz S; Shacter E
Cancer Biochem Biophys; 1995 Jun; 15(1):25-34. PubMed ID: 8536217
[TBL] [Abstract][Full Text] [Related]
9. Specific chromosome translocation in pristane-induced plasmacytomas of NZB mice.
Oikawa T; Kuzumaki N; Yamada T
J Natl Cancer Inst; 1984 Feb; 72(2):347-53. PubMed ID: 6582321
[TBL] [Abstract][Full Text] [Related]
10. Pristane-induced autoimmunity in germ-free mice.
Mizutani A; Shaheen VM; Yoshida H; Akaogi J; Kuroda Y; Nacionales DC; Yamasaki Y; Hirakata M; Ono N; Reeves WH; Satoh M
Clin Immunol; 2005 Feb; 114(2):110-8. PubMed ID: 15639644
[TBL] [Abstract][Full Text] [Related]
11. Differences in the induction of tumorspecific T suppressor lymphocytes among the peritoneal exudate cells in histocompatible BALB/cAnPt and BALB/cJ mouse sublines.
Lügering N; Kölsch E
Immunobiology; 1991 Dec; 184(1):106-10. PubMed ID: 1839294
[TBL] [Abstract][Full Text] [Related]
12. Perturbation of B cell genesis in the bone marrow of pristane-treated mice. Implications for plasmacytoma induction.
Rico-Vargas SA; Potter M; Osmond DG
J Immunol; 1995 Mar; 154(5):2082-91. PubMed ID: 7868885
[TBL] [Abstract][Full Text] [Related]
13. Induction of plasmacytomas with silicone gel in genetically susceptible strains of mice.
Potter M; Morrison S; Wiener F; Zhang XK; Miller FW
J Natl Cancer Inst; 1994 Jul; 86(14):1058-65. PubMed ID: 8021954
[TBL] [Abstract][Full Text] [Related]
14. BALB/c.CBA/N mice carrying the defective Btk(xid) gene are resistant to pristane-induced plasmacytomagenesis.
Potter M; Wax JS; Hansen CT; Kenny JJ
Int Immunol; 1999 Jul; 11(7):1059-64. PubMed ID: 10383938
[TBL] [Abstract][Full Text] [Related]
15. Gas chromatographic-mass spectrometric investigation of four commercial pristane (2.6.10.14-tetramethylpentadecane) preparations used for plasmacytoma induction in BALB/c mice.
Janz S; Birkenfeld T; Herzschuh R; Storch H
Arch Geschwulstforsch; 1989; 59(6):415-22. PubMed ID: 2596957
[TBL] [Abstract][Full Text] [Related]
16. Plasmacytoma induction in specific pathogen-free (SPF) bcl-2 transgenic BALB/c mice.
Silva S; Klein G
Curr Top Microbiol Immunol; 1999; 246():379-85. PubMed ID: 10396078
[TBL] [Abstract][Full Text] [Related]
17. Peritoneal plasmacytomagenesis in mice: comparison of different pristane dose regimens.
Potter M; Wax JS
J Natl Cancer Inst; 1983 Aug; 71(2):391-5. PubMed ID: 6576197
[TBL] [Abstract][Full Text] [Related]
18. Detection of immunoglobulin/c-myc recombinations in mice that are resistant to plasmacytoma induction.
Müller JR; Jones GM; Potter M; Janz S
Cancer Res; 1996 Jan; 56(2):419-23. PubMed ID: 8542601
[TBL] [Abstract][Full Text] [Related]
19. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.
Lattanzio G; Libert C; Aquilina M; Cappelletti M; Ciliberto G; Musiani P; Poli V
Am J Pathol; 1997 Sep; 151(3):689-96. PubMed ID: 9284817
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of plasmacytoma development in BALB/c mice by indomethacin.
Potter M; Wax JS; Anderson AO; Nordan RP
J Exp Med; 1985 May; 161(5):996-1012. PubMed ID: 3989472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
